QDEL FY2025 SEC EDGAR DEF 14A #23 of 168 in industry

QuidelOrtho Corp CEO pay ratio

The CEO earned $11.3M in FY2025 against median worker pay of $73,316 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
CA
Filing date
2026-04-27
Industry
Chemicals & Pharmaceuticals
Industry rank
#23/168

Data updated August 2026

Subscribe to QuidelOrtho Corp CEO pay filing updates (RSS)

CEO-to-worker pay ratio
154:1
High (Scale: 0–1000:1)
CEO pay
$11.3M
Median worker
$73,316

Answer first

QuidelOrtho Corp's FY2025 CEO total of $11.3M ranks #452 of 1,423 complete filings; its 154:1 pay ratio ranks #423. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $73,316. Industry placement uses the FY2025 SIC-28 peer cohort (# 23 of 168, 87th percentile - top quartile of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#452
$11.3M of 1,423 FY2025
Ratio rank
#423
154:1 of 1,423
Industry pct
87th
top quartile of industry peers by pay ratio

How QuidelOrtho Corp ranks nationally

QuidelOrtho Corp CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$11,290,664 Top 32% higher than 68% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). Below this entry. $10,000,000–$12,500,000: 139 companies (10%). This entry sits in this band. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

QuidelOrtho Corp vs. Chemicals & Pharmaceuticals peers

CEO total pay ($11.3M) against pay ratio (154:1) for QuidelOrtho Corp (marked) and its 4 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both06948028.813896057.720844086.527792115.335.8:169.9:1104.0:1138.1:1172.2:1CEO total payPay ratio (CEO : median worker)QuidelOrtho Corp, CEO total pay: 11290664 · Pay ratio (CEO : median worker): 154:1QuidelOrtho CorpElement Solutions Inc, CEO total pay: 26480462 · Pay ratio (CEO : median worker): 153:1Element Solutions IncAmgen Inc, CEO total pay: 24693120 · Pay ratio (CEO : median worker): 160:1Amgen IncOcular Therapeutix, Inc, CEO total pay: 247396 · Pay ratio (CEO : median worker): 145:1Ocular Therapeutix, IncAbbott Laboratories, CEO total pay: 24157648 · Pay ratio (CEO : median worker): 166:1Abbott Laboratories
QuidelOrtho Corp vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in QuidelOrtho Corp's structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · QuidelOrtho Corp

Complete DEF 14A pay-ratio filings for this CIK across FY2022–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
154:1
FY2025
vs prior FY
-14:1
from FY2024 168:1
CEO $ YoY
-25%
$11.3M latest
Filings shown
4
FY2022–2025
QuidelOrtho Corp CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2022 $13.1M - $77,372 169:1 -
2023 $6.8M -48% $98,005 69:1 -100:1
2024 $15.0M +122% $89,322 168:1 +99:1
2025 $11.3M -25% $73,316 154:1 -14:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1906324, FY2022–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
154:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$11.3M
Companies in Industry
168
vs. Industry Median
Above
#23 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

QuidelOrtho Corp: STEEP · HEAVY pay ratio

QuidelOrtho Corp's FY2025 ratio 154:1 ranks #23 of 168 Chemicals & Pharmaceuticals filers (87th percentile). the CEO earned 154× the median employee ($73,316) in FY2025.

Median employee $73,316 (HIGH-MED); STEEP · HEAVY stamps put about 154 median-wage years per CEO year.

CEO Total Pay

$11.3M

FY2025 Summary Compensation, above median

Pay Ratio

154:1

Elevated vs. peers

QuidelOrtho Corp in the higher Chemicals & Pharmaceuticals third

QuidelOrtho Corp's FY2025 ratio 154:1 ranks #23 of 168 Chemicals & Pharmaceuticals filers (87th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; QuidelOrtho Corp's $11.3M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #452 and ratio rank #423 split - treat 154:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$11.3M
Median Employee Pay
$73,316
Pay Ratio
154:1
Filing Date
2026-04-27

Company Info

Ticker
QDEL
CIK
1906324
Industry
Chemicals & Pharmaceuticals
SIC Code
2835
State
CA
View SEC filings →
SEC EDGAR DEF 14A for CIK 1906324, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. QuidelOrtho Corp's FY2025 ratio 154:1 ranks #23 of 168 Chemicals & Pharmaceuticals filers (87th percentile).

Read with QuidelOrtho Corp

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps STEEP · HEAVY · HIGH-MED.

Silicon Laboratories Inc. · HEAVY

ABS(ceo_total_comp) peer at $11.3M (Δ $5K heavier vs QuidelOrtho Corp); MID · HIGH-MED vs this page's STEEP · HEAVY · HIGH-MED.
Xylem Inc. · HEAVY

ABS(ceo_total_comp) peer at $11.3M (Δ $20K heavier vs QuidelOrtho Corp); STEEP · PAR-MED vs this page's STEEP · HEAVY · HIGH-MED.
SLM Corp · HEAVY

ABS(ceo_total_comp) peer at $11.3M (Δ $29K lighter vs QuidelOrtho Corp); MID · HIGH-MED vs this page's STEEP · HEAVY · HIGH-MED.
Alignment Healthcare, Inc. · HEAVY

ABS(ceo_total_comp) peer at $11.3M (Δ $32K lighter vs QuidelOrtho Corp); STEEP · HIGH-MED vs this page's STEEP · HEAVY · HIGH-MED.
Element Solutions Inc (SIC 28 pole)

Element Solutions Inc stamps STEEP · PEAK nearest in-SIC by ABS(pay_ratio) to QuidelOrtho Corp's STEEP filing.
National dual ranks · #452/#423

QuidelOrtho Corp's FY2025 package sits #452 by CEO dollars and #423 by ratio under HEAVY · STEEP.
Comp structure · HEAVY

QuidelOrtho Corp's HEAVY CEO total is equity-sensitive - read what grant-date fair value does and does not mean.
Data sourced from SEC EDGAR DEF 14A for QuidelOrtho Corp (CIK 1906324), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.